Private equity firms are circling the speech therapy market, drawn by rising demand from early intervention programs that are diagnosing more children with conditions requiring these services. General Atlantic, Aquitaine Capital, Avesi Partners, and PPC Enterprises are among the investors recognizing the sector's growth potential.

Early intervention initiatives have shifted toward identifying speech and communication disorders in children sooner, creating a larger addressable market for therapy providers. This demographic trend has made the segment increasingly attractive to financial sponsors seeking stable, recurring revenue streams in healthcare services.

Meanwhile, Apotex has launched what ranks as the largest life sciences IPO in Toronto Stock Exchange history, raising C$1.3 billion. The offering comes from the SK Capital-backed generic drug manufacturer, capitalizing on stable pharmaceutical demand amid ongoing market conditions.

Both developments reflect broader healthcare investing trends: investors are pursuing specialized services with predictable growth while established pharmaceutical companies tap public markets for expansion capital. The dual focus on therapeutic services and drug manufacturing signals sustained appetite for healthcare assets.